See more : Raghuvansh Agrofarms Limited (RAFL.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Anika Therapeutics, Inc. (ANIK) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Anika Therapeutics, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Hainan Manaslu Acquisition Corp. (HMACW) Income Statement Analysis – Financial Results
- Albina Community Bancorp (ACBCQ) Income Statement Analysis – Financial Results
- Intralot S.A. Integrated Lottery Systems and Services (IRLTF) Income Statement Analysis – Financial Results
- Costamare Inc. (CMRE) Income Statement Analysis – Financial Results
- CNOOC Energy Technology & Services Limited (600968.SS) Income Statement Analysis – Financial Results
Anika Therapeutics, Inc. (ANIK)
About Anika Therapeutics, Inc.
Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management product family consists of Monovisc, Orthovisc, Cingal, and Hyvisc that are indicated to provide pain relief from osteoarthritis conditions; and joint preservation and restoration product family comprise a portfolio of approximately 150 bone preserving joint technology products, a line of sports medicine soft tissue repair solutions, and orthopedic regenerative solutions products. The company's non-orthopedic product family include HA-based products for non-orthopedic applications, including adhesion barrier products, advanced wound care products, ophthalmic products, and ear, nose, and throat products. Anika Therapeutics, Inc. was founded in 1983 and is headquartered in Bedford, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 166.66M | 156.24M | 147.79M | 130.46M | 114.61M | 105.56M | 113.42M | 103.38M | 93.00M | 105.59M | 75.08M | 71.36M | 64.78M | 55.56M | 40.14M | 35.78M | 30.83M | 26.84M | 29.84M | 26.47M | 15.40M | 13.19M | 11.31M | 16.34M | 13.50M | 13.90M | 12.00M | 1.20M | 3.40M | 4.70M | 2.20M |
| Cost of Revenue | 63.57M | 62.66M | 64.85M | 61.43M | 28.75M | 31.28M | 27.36M | 24.03M | 21.05M | 20.93M | 22.77M | 28.99M | 26.78M | 23.83M | 13.67M | 13.19M | 11.88M | 11.12M | 11.14M | 9.95M | 8.01M | 8.11M | 8.23M | 8.67M | 5.30M | 5.20M | 4.40M | 700.00K | 2.80M | 3.70M | 1.90M |
| Gross Profit | 103.09M | 93.58M | 82.94M | 69.03M | 85.86M | 74.28M | 86.06M | 79.35M | 71.95M | 84.66M | 52.32M | 42.37M | 37.99M | 31.73M | 26.47M | 22.59M | 18.95M | 15.72M | 18.69M | 16.52M | 7.40M | 5.08M | 3.08M | 7.66M | 8.20M | 8.70M | 7.60M | 500.00K | 600.00K | 1.00M | 300.00K |
| Gross Profit Ratio | 61.85% | 59.89% | 56.12% | 52.91% | 74.92% | 70.37% | 75.87% | 76.76% | 77.36% | 80.18% | 69.68% | 59.38% | 58.65% | 57.11% | 65.94% | 63.14% | 61.46% | 58.58% | 62.65% | 62.41% | 48.03% | 38.51% | 27.26% | 46.91% | 60.74% | 62.59% | 63.33% | 41.67% | 17.65% | 21.28% | 13.64% |
| Research & Development | 32.69M | 28.18M | 27.33M | 23.43M | 16.67M | 18.19M | 18.79M | 10.73M | 8.99M | 8.14M | 7.06M | 5.39M | 6.17M | 6.87M | 8.18M | 7.40M | 4.36M | 3.62M | 4.73M | 4.09M | 2.60M | 3.93M | 4.28M | 3.26M | 4.20M | 2.00M | 2.00M | 0.00 | 1.30M | 1.50M | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 34.34M | 21.54M | 18.01M | 14.83M | 15.07M | 12.94M | 14.73M | 17.86M | 17.32M | 10.55M | 10.97M | 8.00M | 6.68M | 5.41M | 6.04M | 4.21M | 4.42M | 6.21M | 4.19M | 3.00M | 2.70M | 2.10M | 0.00 | 900.00K | 700.00K | 1.90M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 95.85M | 84.79M | 74.10M | 60.06M | 34.95M | 34.34M | 21.54M | 18.01M | 14.83M | 15.07M | 12.94M | 14.73M | 17.86M | 17.32M | 10.55M | 10.97M | 8.00M | 6.68M | 5.41M | 6.04M | 4.21M | 4.42M | 6.21M | 4.19M | 3.00M | 2.70M | 2.10M | 2.60M | 900.00K | 700.00K | 1.90M |
| Other Expenses | 62.19M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.54B | 0.00 | 0.00 | 2.15B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.20M | 1.10M | 800.00K | 300.00K | 600.00K | 300.00K | 200.00K | 300.00K |
| Operating Expenses | 191.48M | 112.98M | 101.42M | 83.49M | 51.62M | 52.53M | 40.33M | 28.75M | 23.81M | 23.22M | 20.00M | 20.12M | 24.03M | 24.19M | 18.73M | 18.36M | 12.36M | 10.30M | 10.14M | 10.13M | 6.80M | 8.35M | 10.49M | 8.65M | 8.30M | 5.50M | 4.40M | 3.20M | 2.50M | 2.40M | 2.20M |
| Cost & Expenses | 254.30M | 175.64M | 166.27M | 144.93M | 80.36M | 83.81M | 67.69M | 52.77M | 44.87M | 44.15M | 42.76M | 49.11M | 50.81M | 48.02M | 32.40M | 31.55M | 24.24M | 21.41M | 21.28M | 20.08M | 14.81M | 16.46M | 18.72M | 17.32M | 13.60M | 10.70M | 8.80M | 3.90M | 5.30M | 6.10M | 4.10M |
| Interest Income | 0.00 | 654.00K | 188.00K | 498.00K | 1.87M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 186.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 654.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 127.19K | 5.26M | 182.39K | 194.62K | 4.38M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 14.22M | 16.35M | 15.99M | 15.00M | 7.17M | 5.91M | 4.29M | 3.73M | 3.78M | 4.71M | 4.77M | 4.53M | 4.00M | 3.32M | 1.29M | 1.43M | 818.73K | 384.06K | 459.00K | 710.00K | 1.01M | 1.10M | 1.23M | 1.20M | 1.10M | 800.00K | 300.00K | 600.00K | 300.00K | 200.00K | 300.00K |
| EBITDA | -11.23M | -4.91M | 2.62M | -12.83M | 34.25M | 27.66M | 50.02M | 54.34M | 51.91M | 61.45M | 32.03M | 26.78M | 17.97M | 10.86M | 11.18M | 5.66M | 7.41M | 5.81M | 9.01M | 14.53M | 1.60M | -2.18M | -6.18M | 214.38K | 1.10M | 3.37M | 3.50M | -2.10M | -1.60M | -1.20M | -1.60M |
| EBITDA Ratio | -6.74% | -12.42% | -26.78% | -0.47% | 29.88% | 20.60% | 40.32% | 48.95% | 51.76% | 58.19% | 42.66% | 34.74% | 27.74% | 19.54% | 27.87% | 15.82% | 24.02% | 21.65% | 30.20% | 26.82% | 10.39% | -16.53% | -54.61% | 1.31% | 5.93% | 19.42% | 26.67% | -183.33% | -47.06% | -27.66% | -72.73% |
| Operating Income | -87.64M | -19.40M | -18.48M | -14.47M | 34.25M | 21.75M | 45.73M | 50.61M | 48.13M | 61.45M | 32.61M | 19.72M | 13.97M | 7.54M | 5.59M | 4.23M | 6.59M | 5.43M | 8.55M | 6.39M | 595.00K | -3.27M | -7.41M | -983.37K | -100.00K | 3.20M | 3.20M | -2.70M | -1.90M | -1.40M | -1.90M |
| Operating Income Ratio | -52.58% | -12.42% | -12.50% | -11.09% | 29.88% | 20.60% | 40.32% | 48.95% | 51.76% | 58.19% | 43.43% | 27.63% | 21.56% | 13.57% | 13.92% | 11.81% | 21.37% | 20.22% | 28.66% | 24.14% | 3.86% | -24.83% | -65.51% | -6.02% | -0.74% | 23.02% | 26.67% | -225.00% | -55.88% | -29.79% | -86.36% |
| Total Other Income/Expenses | 2.31M | 654.00K | -188.00K | -302.00K | 1.87M | 1.46M | 473.00K | 263.00K | 120.00K | 58.14K | -127.00K | -187.78K | -182.39K | -194.62K | -2.23M | 498.51K | 2.10M | 2.10M | 1.24M | 388.71K | 144.00K | 239.00K | 662.19K | 1.17M | 1.38M | 700.00K | 200.00K | 100.00K | 0.00 | 100.00K | 0.00 |
| Income Before Tax | -85.33M | -18.75M | 2.43M | -28.62M | 36.12M | 23.21M | 46.20M | 50.87M | 48.25M | 61.51M | 32.48M | 19.53M | 13.79M | 7.34M | 5.51M | 4.73M | 8.69M | 7.53M | 9.79M | 6.78M | 739.00K | -3.03M | -6.75M | 189.49K | -100.00K | 4.40M | 3.40M | -2.60M | 0.00 | -1.30M | -1.90M |
| Income Before Tax Ratio | -51.20% | -12.00% | 1.64% | -21.94% | 31.52% | 21.99% | 40.74% | 49.21% | 51.89% | 58.25% | 43.26% | 27.37% | 21.28% | 13.22% | 13.73% | 13.21% | 28.18% | 28.05% | 32.82% | 25.61% | 4.80% | -23.02% | -59.66% | 1.16% | -0.74% | 31.65% | 28.33% | -216.67% | 0.00% | -27.66% | -86.36% |
| Income Tax Expense | -2.66M | -3.89M | -1.71M | -4.64M | 8.93M | 4.49M | 14.39M | 18.32M | 17.50M | 23.19M | 11.91M | 7.77M | 5.32M | 3.03M | 1.82M | 1.10M | 2.65M | 2.92M | 3.90M | -4.41M | -88.00K | 5.00K | 9.08K | 15.94K | 2.20M | 100.00K | 100.00K | -100.00K | 100.00K | -100.00K | -300.00K |
| Net Income | -82.67M | -14.86M | 4.13M | -23.98M | 27.19M | 18.72M | 31.82M | 32.55M | 30.76M | 38.32M | 20.57M | 11.76M | 8.47M | 4.32M | 3.69M | 3.63M | 6.04M | 4.60M | 5.89M | 11.19M | 827.00K | -3.04M | -6.76M | 173.55K | -2.50M | 4.30M | 3.30M | -2.70M | -2.00M | -1.40M | -1.60M |
| Net Income Ratio | -49.60% | -9.51% | 2.80% | -18.38% | 23.73% | 17.74% | 28.05% | 31.48% | 33.07% | 36.29% | 27.40% | 16.48% | 13.07% | 7.77% | 9.19% | 10.14% | 19.58% | 17.15% | 19.75% | 42.28% | 5.37% | -23.05% | -59.74% | 1.06% | -18.52% | 30.94% | 27.50% | -225.00% | -58.82% | -29.79% | -72.73% |
| EPS | -5.64 | -1.02 | 0.29 | -1.69 | 1.93 | 1.30 | 2.18 | 2.22 | 2.06 | 2.61 | 1.46 | 0.89 | 0.65 | 0.34 | 0.32 | 0.32 | 0.55 | 0.43 | 0.57 | 0.98 | 0.08 | -0.31 | -0.68 | 0.02 | -0.26 | 0.38 | 0.60 | -0.56 | -0.61 | -0.45 | -0.51 |
| EPS Diluted | -5.64 | -1.02 | 0.28 | -1.69 | 1.89 | 1.27 | 2.11 | 2.15 | 2.01 | 2.51 | 1.39 | 0.82 | 0.62 | 0.32 | 0.32 | 0.32 | 0.53 | 0.41 | 0.52 | 0.98 | 0.08 | -0.31 | -0.68 | 0.02 | -0.24 | 0.34 | 0.44 | -0.56 | -0.61 | -0.45 | -0.51 |
| Weighted Avg Shares Out | 14.66M | 14.56M | 14.40M | 14.22M | 14.12M | 14.44M | 14.58M | 14.68M | 14.93M | 14.68M | 14.09M | 13.26M | 13.06M | 12.62M | 11.39M | 11.31M | 11.06M | 10.64M | 10.41M | 11.42M | 9.95M | 9.93M | 9.93M | 9.87M | 9.74M | 9.89M | 5.00M | 4.82M | 3.28M | 3.11M | 3.14M |
| Weighted Avg Shares Out (Dil) | 14.66M | 14.56M | 14.63M | 14.22M | 14.37M | 14.69M | 15.07M | 15.12M | 15.32M | 15.27M | 14.83M | 14.34M | 13.75M | 13.65M | 11.56M | 11.46M | 11.45M | 11.16M | 11.43M | 11.42M | 10.85M | 9.93M | 9.93M | 10.04M | 10.22M | 11.01M | 7.50M | 4.82M | 3.28M | 3.11M | 3.14M |
Anika Therapeutics, Inc. (ANIK) Q3 2022 Earnings Call Transcript
Anika Therapeutics, Inc. (NASDAQ:ANIK ) Q3 2022 Results Conference Call November 8, 2022 5:00 PM ET Company Participants Mark Namaroff - Vice President, Investor Relations, ESG and Corporate Communications Dr. Cheryl Blanchard - President and Chief Executive Officer Mike Levitz...
Anika Reports Third Quarter Fiscal 2022 Financial Results
Third Quarter Revenue Growth of 2%
Anika's Cingal® Successfully Achieves Primary Endpoint in Third Phase III Study
Study Demonstrated Superiority of Cingal, a Single-Injection Hyaluronic Acid-Based Viscosupplement Combined with Fast-Acting Steroid, Over Steroid Alone, for Osteoarthritis Pain Relief at 26 Weeks
Anika to Issue Third Quarter 2022 Financial Results on Tuesday, November 8, 2022
BEDFORD, Mass., Oct. 25, 2022 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that the Company plans to issue its third quarter 2022 financial results after the close of...
Anika Announces First Surgeries Performed Using the X-Twist™ Fixation System and Commences Limited Market Release
X-Twist expands Anika's sports medicine portfolio with a cornerstone suture anchor system ideal for key repairs in the shoulder, foot and ankle, and other extremities X-Twist expands Anika's sports medicine portfolio with a cornerstone suture anchor system ideal for key...
Anika Therapeutics Inc. (ANIK) CEO Cheryl Blanchard on Q2 2022 Results - Earnings Call Transcript
Anika Therapeutics, Inc. (NASDAQ:ANIK ) Q2 2022 Earnings Conference Call August 3, 2022 5:00 PM ET Company Participants Mark Namaroff - Vice President, Investor Relations, ESG and Corporate Communications Cheryl Blanchard - President and Chief Executive Officer Michael Levitz -...
Anika Reports Second Quarter Fiscal 2022 Financial Results
Second quarter revenue growth up 4% X-Twist ™ 510(k) clearance received; Limited market release on schedule for 2H 2022
Anika Receives the ACE Award for Cutting-Edge Innovation for Tactoset® Injectable Bone Substitute from the American Orthopedic Society for Sports Medicine
BEDFORD, Mass., July 27, 2022 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company focused on early intervention orthopedics, today announced that it has received the Accelerating the Cutting Edge (ACE) Award from the American Orthopaedic Society...
Anika to Issue Second Quarter 2022 Financial Results on Wednesday, August 3, 2022
BEDFORD, Mass., July 12, 2022 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that the Company plans to issue its second quarter 2022 financial results after the close of...
Anika to Participate in the Sidoti Small Cap Virtual Investor Conference
BEDFORD, Mass., June 10, 2022 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that management will participate in the Sidoti Small Cap Virtual Investor Conference on Wednesday, June 15,...
Source: https://incomestatements.info
Category: Stock Reports